Our Annual Report features ten of the year’s most important research and clinical advances, the result of work led by physician-scientists and basic-science investigators.

Memorial Sloan-Kettering has announced its intention to build a new, state-of-the-art outpatient cancer treatment facility on Manhattan’s Upper East Side.

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan-Kettering from Massachusetts General Hospital.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

We recently launched our first-ever television advertising campaign, which offers a sense of the passion and compassion that defines how we care for people with cancer.

A new Memorial Sloan-Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.